Figure 1a



Sequence of SC104 Variable Domain IGg1 Heavy Chain
Forward Heavy Chain Primer
FR1
Signal Leader Sequence
CDR1
FR2
CDR2
FR3
CDR3
FR4
CH1
Constant domain
Reverse Heavy Chain CH1 Primer

Figure 1b (Kabat numbering)




Figure 1c

Sequence of SC104 Variable Domain Kappa Light Chain





Figure 1d Binding of chimeric SC104 to the cell surface of C170 cells



Anti-human FC specfic FITC 2ndry alone

Chimeric SC104 supernatant / Anti-human FC specific FITC

Overlay

Figure 2a Binding of SC104 mab to tumour cell lines




Figure 2b SC104 mab binding to different tumour cell lines




Figure 3




Figure 4 SC104 binding to glycolipid extract, CEA and C14 antigen





Figure 5


A
R_F 0.53
W 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
B
W 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21




Figure 6




Figure 7




Figure 8





Figure 9

Figure 10






Figure 11

Figure 12




Figure 13





Figure 14 - Silver stained gel showing SC104 immuno-purified antigen using the SC104-Protein A sepharose column



M= BioRad markers, 1 = sputum; 2 = unbound from column; 3 = 0.1M Tris pH 7.6 0.5% NP40; 4 = 0.1M Tris pH 7.6 0.2% NP40 1M NaCl; 5 = 0.1 M Tris pH 7.6 0.1% NP40; 6= 0.1M Tris pH7.6; 7 = Diethanol amine pH 11.5 eluted pooled fraction

Figure 15 - The purified SC104 fraction from sputum competing with SC104 biotin for binding to C170 cells




Figure 16




Figure 17 - FITC-FMK-vad flow showing activation of pan caspase in adherent C170 cells




Figure 18 - Caspase 6 Western blot of C170 cells exposed to SC104




Figure 19 - SC104 Inhibition of cell death: z-FMK-vad caspase inhibitor




Figure 20 - Cell Inhibition Assays




Figure 21 - SC104 IC_{50}s for C170, Colo205, HT-29 and LoVo's




Figure 22



10000
9000
8000
7000
6000
5000
4000
3000
2000
1000
0
MLF
0.1
1
10
100
[SC104] (μg/ml)
Media
0.5% Gluteraldehyde
Cellfix

Figure 23a - SC104 Homophilic binding




Figure 23b - Homophilic binding of SC104 in the presence of C14 antigen




Figure 24




Figure 25 - SC104 Synergy with a range of chemotherapeutic drugs




Figure 26a - Increase in tumour cross-sectional area





Figure 26b - Survival Assessment



Statistical Analysis, LOG RANK:

1:4 p = 0.0038
2:4 p = 0.0111

Figure 26c - Mouse weights





Figure 27 - Therapeutic Survival Assessment



This data was obtained from the CSU749a study. SC104 plus 5-FU/leucovorin exhibited a significant reduction in final weight/time and inhibited tumour growth with enhanced survival in the C170 subcutaneous xenograft model.

Sequence listing

<110> Arana Therapeutics Limited

<120> Specifc Binding Members

<130> SP8160A

<150> GB 0410627.4
<151> 2004-05-12

<160> 28

<170> PatentIn version 3.2

<210> 1
<211> 23
<212> DNA
<213> Artificial

<220>
<223> Forward Primer (Heavy Chain)

<400> 1
atgagagtgc tgattctttt gtg
23

<210> 2
<211> 30
<212> DNA
<213> Artificial

<220>
<223> Forward Primer (Kappa Chain)

<400> 2
atggatttwc argtgcagat twtcagcttc
30

<210> 3
<211> 35
<212> DNA
<213> Artificial

<220>
<223> Reverse Primer (Heavy Chain)

<400> 3
cccaagcttc cagggrccar kggataracg grtgg
35

<210> 4
<211> 30

<212> DNA
<213> Artificial

<220>
<223> Reverse Primer (Kappa Chain)

<400> 4
cccaagctta ctggatggtg ggaagatgga
30

<210> 5
<211> 11
<212> PRT
<213> Mus musculus

<400> 5

Gly Tyr Ser Ile Thr Ser Gly Tyr Ser Trp His
1 5 10

<210> 6
<211> 33
<212> DNA
<213> Mus musculus

<400> 6
ggctactcca tcacgagtgg ttatagttgg cac
33

<210> 7
<211> 6
<212> PRT
<213> Mus musculus

<400> 7

Ser Gly Tyr Ser Trp His
1 5

<210> 8
<211> 18
<212> DNA
<213> Mus musculus

<400> 8
agtggttata gttggcac
18

<210> 9
<211> 16
<212> PRT
<213> Mus musculus

<400> 9

His Ile His Phe Ser Gly Arg Pro Thr Tyr Asn Pro Ser Leu Ser Ser
1 5 10 15

<210> 10
<211> 48
<212> DNA
<213> Mus musculus

<400> 10
cacattcact tcagtggtag acctacttac aatccatctc tcagcagt
48

<210> 11
<211> 11
<212> PRT
<213> Mus musculus

<400> 11

Lys Gly Lys Gly Ser Asp Asp Gly Leu Asn Tyr
1 5 10

<210> 12
<211> 33
<212> DNA
<213> Mus musculus

<400> 12
aagggaaaag gttccgacga tggtttgaac tac
33

<210> 13
<211> 10
<212> PRT
<213> Mus musculus

<400> 13

Ser Ala Ser Ser Ser Leu Ser Tyr Ile His
1 5 10

<210> 14
<211> 30
<212> DNA
<213> Mus musculus

<400> 14
agtgccagct caagtttaag ttacatacac
30

<210> 15
<211> 7
<212> PRT
<213> Mus musculus

<400> 15

Asp Thr Ser Asn Leu Ala Ser
1 5

<210> 16
<211> 21
<212> DNA
<213> Mus musculus

<400> 16
gacacatcca acctggcttc t
21

<210> 17
<211> 9
<212> PRT
<213> Mus musculus

<400> 17

Phe Gln Gly Ser Glu Tyr Pro Leu Thr
1 5

<210> 18
<211> 27
<212> DNA
<213> Mus musculus

<400> 18
tttcagggga gtgagtatcc actcacg
27

<210> 19
<211> 39
<212> DNA
<213> Mus musculus

<400> 19
ctcagtcacc gtctctagcg ctaaaacgac acccccacc
39

<210> 20
<211> 39
<212> DNA
<213> Mus musculus

<400> 20
ggtgggggtg tcgttttagc gctagagacg gtgactgag
39

<210> 21
<211> 39
<212> DNA
<213> Mus musculus

<400> 21
ccaagctgga aatgacacgt acggatgctg caccaactg
39

<210> 22
<211> 39
<212> DNA

<213> Mus musculus

<400> 22
cagttggtgc agcatccgta cgtgtcattt ccagcttgg
39

<210> 23
<211> 154
<212> PRT
<213> Mus musculus

<400> 23

Met Arg Val Leu Ile Leu Leu Cys Leu Phe Thr Ala Phe Pro Gly Ile
1 5 10 15

Leu Ser Asp Val Gln Leu Gln Glu Ser Gly Pro Asp Leu Val Lys Pro
20 25 30

Ser Gln Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr
35 40 45

Ser Gly Tyr Ser Trp His Trp Val Arg Gln Phe Pro Gly Asn Lys Met
50 55 60

Glu Trp Met Gly His Ile His Phe Ser Gly Arg Pro Thr Tyr Asn Pro
65 70 75 80

Ser Leu Ser Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln
85 90 95

Phe Leu Leu Gln Leu Lys Phe Val Thr Thr Glu Asp Thr Ser Thr Tyr

100 105 110

Phe Cys Ala Arg Lys Gly Lys Gly Ser Asp Asp Gly Leu Asn Tyr Trp
115 120 125

Gly Gln Gly Ile Ser Val Thr Val Ser Ser Ala Lys Thr Thr Pro Pro
130 135 140

Pro Val Tyr Pro Leu Val Pro Gly Ser Leu
145 150

<210> 24
<211> 463
<212> DNA
<213> Mus musculus

<400> 24
atgagagtgc tgattctttt gtgcctgttc acagcctttc ctggtatcct gtctgatgtg
60

cagcttcagg agtcaggacc tgacctggtg aaaccttctc agtcactttc actcacctgc
120

actgtcactg gctactccat cacgagtggt tatagttggc actgggtccg gcagtttcca
180

ggaaacaaaa tggaatggat gggccacatt cacttcagtg gtagacctac ttacaatcca
240

tctctcagca gtcgaatctc gatcactcga gacacatcca agaaccagtt cctcctgcaa
300

ttgaaatttg tgactactga agacacatcc acatattttt gtgcaaggaa gggaaaaggt
360

tccgacgatg gtttgaacta ctggggtcaa ggaatctcag tcaccgtctc ttcagccaaa
420

acgacacccc cacccgttta tcccttggtc cctggaagct tgg
463

<210> 25
<211> 154
<212> PRT
<213> Mus musculus

<400> 25

Met Arg Val Leu Ile Leu Leu Cys Leu Phe Thr Ala Phe Pro Gly Ile
1 5 10 15

Leu Ser Asp Val Gln Leu Gln Glu Ser Gly Pro Asp Leu Val Lys Pro
20 25 30

Ser Gln Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr
35 40 45

Ser Gly Tyr Ser Trp His Trp Val Arg Gln Phe Pro Gly Asn Lys Met
50 55 60

Glu Trp Met Gly His Ile His Phe Ser Gly Arg Pro Thr Tyr Asn Pro
65 70 75 80

Ser Leu Ser Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln
85 90 95

Phe Leu Leu Gln Leu Lys Phe Val Thr Thr Glu Asp Thr Ser Thr Tyr
100 105 110

Phe Cys Ala Arg Lys Gly Lys Gly Ser Asp Asp Gly Leu Asn Tyr Trp
115 120 125

Gly Gln Gly Ile Ser Val Thr Val Ser Ser Ala Lys Thr Thr Pro Pro
130 135 140

Pro Val Tyr Pro Leu Val Pro Gly Ser Leu
145 150

<210> 26
<211> 463
<212> DNA
<213> Mus musculus

<400> 26
atgagagtgc tgattctttt gtgcctgttc acagcctttc ctggtatcct gtctgatgtg
60

cagcttcagg agtcaggacc tgacctggtg aaaccttctc agtcactttc actcacctgc
120

actgtcactg gctactccat cacgagtggt tatagttggc actgggtccg gcagtttcca
180

ggaaacaaaa tggaatggat gggccacatt cacttcagtg gtagacctac ttacaatcca
240

tctctcagca gtcgaatctc gatcactcga gacacatcca agaaccagtt cctcctgcaa
300

ttgaaatttg tgactactga agacacatcc acatattttt gtgcaaggaa gggaaaaggt
360

tccgacgatg gtttgaacta ctggggtcaa ggaatctcag tcaccgtctc ttcagccaaa
420

acgacacccc cacccgttta tcccttggtc cctggaagct tgg
463

<210> 27
<211> 147
<212> PRT
<213> Mus musculus

<400> 27

Met Asp Leu Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser
1 5 10 15

Val Ile Met Ser Arg Gly Glu Asn Val Leu Thr Gln Ser Pro Val Ile
20 25 30

Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser
35 40 45

Ser Ser Leu Ser Tyr Ile His Trp Tyr Gln Gln Lys Ser Arg Thr Ser
50 55 60

Pro Lys Leu Trp Ile Tyr Asp Thr Ser Asn Leu Ala Ser Gly Val Pro
65 70 75 80

Gly Arg Phe Ser Gly Ser Gly Ser Gly Asn Ser Tyr Ser Leu Thr Ile
85 90 95

Ser Ser Met Glu Ala Glu Asp Val Ala Thr Tyr Tyr Cys Phe Gln Gly
100 105 110

Ser Glu Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Met Thr
115 120 125

Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Lys
130 135 140

Leu Gly Lys
145

<210> 28

<211> 443
<212> DNA
<213> Mus musculus

<400> 28

atggatttac aggtgcagat tttcagcttc ctgctaatca gtgcctcagt cataatgtcc
60

agaggagaaa atgttctcac ccagtctcca gtaatcatgt ctgcatctcc aggggaaaag
120

gtcaccatga cctgcagtgc cagctcaagt ttaagttaca tacactggta ccagcagaag
180

tcaagaacct cccccaaact ctggatttat gacacatcca acctggcttc tggagtccca
240

ggtcgcttca gtggcagtgg gtctggaaac tcttattctc tcacgatcag cagcatggag
300

gctgaagatg ttgccactta ttactgtttt caggggagtg agtatccact cacgttcggg
360

gggggacca agctggaaat gacacgggct gatgctgcac caactgtatc catcttccca
420

ccatccagta agcttgggaa ggg
443